Steven Cohen's LRMR Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.05 M shares of Larimar Therapeutics, Inc. (LRMR) worth $4.71 M, representing 0.01% of the portfolio. First purchased in 2020-Q2, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in LRMR, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 1.22 M shares. Largest reduction occurred in Q1 2026, reducing 413,643 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Larimar Therapeutics (LRMR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Larimar Therapeutics (LRMR) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -413,643 | Reduce 28.31% | 1.05 M | $4.50 |
| Q4 2025 | +237,162 | Add 19.38% | 1.46 M | $3.81 |
| Q3 2025 | +1.22 M | New Buy | 1.22 M | $3.23 |
| Q4 2024 | -207,100 | Sold Out | 0 | $0.00 |
| Q3 2024 | -396,481 | Reduce 65.69% | 207,100 | $6.55 |
| Q2 2024 | +165,181 | Add 37.68% | 603,581 | $7.25 |
| Q1 2024 | -12,000 | Reduce 2.66% | 438,400 | $7.59 |
| Q4 2023 | -4,600 | Reduce 1.01% | 450,400 | $4.55 |
| Q3 2023 | -384,000 | Reduce 45.77% | 455,000 | $3.95 |
| Q2 2023 | +384,000 | Add 84.40% | 839,000 | $3.13 |
| Q1 2023 | -20,000 | Reduce 4.21% | 455,000 | $4.53 |
| Q3 2022 | +475,000 | New Buy | 475,000 | $3.20 |
| Q1 2022 | -196,896 | Sold Out | 0 | $0.00 |
| Q3 2021 | +97,736 | Add 98.56% | 196,896 | $11.53 |
| Q2 2021 | +81,900 | Add 474.51% | 99,160 | $9.82 |
| Q2 2020 | +17,260 | New Buy | 17,260 | $12.86 |
Steven Cohen's Larimar Therapeutics Investment FAQs
Steven Cohen first purchased Larimar Therapeutics, Inc. (LRMR) in Q2 2020, acquiring 17,260 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Larimar Therapeutics, Inc. (LRMR) for 21 quarters since Q2 2020.
Steven Cohen's largest addition to Larimar Therapeutics, Inc. (LRMR) was in Q3 2025, adding 1,223,866 shares worth $3.95 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,047,385 shares of Larimar Therapeutics, Inc. (LRMR), valued at approximately $4.71 M.
As of the Q1 2026 filing, Larimar Therapeutics, Inc. (LRMR) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Larimar Therapeutics, Inc. (LRMR) was 1,461,028 shares, as reported at the end of Q4 2025.